Cardiometabolic Medicine: Development of a New Subspecialty

David R. Saxon; Cara Reiter-Brennan; Michael J. Blaha; Robert H. Eckel


J Clin Endocrinol Metab. 2020;105(7):2095-2104. 

In This Article


Change in medicine does not come easily and we expect that there will be objections to the development of this new subspecialty. Some endocrinologists might be concerned that diabetes management will be oversimplified and bleed out to cardiologists. Cardiologists may feel that the absence of certain areas of traditional cardiology training from the program means that trainees will lack specific expertise that will be required to care for high-risk cardiac patients, or that imaging training will be insufficient for clinical interpretations. Such concerns may be valid in certain settings, but, overall, we feel that establishing Cardiometabolic Medicine as a field, although not a quick fix for high-risk metabolic patients, is fitting for the times we live in based on the current trajectories of disease we will face as a society.

The growing prevalence of cardiometabolic disease is one of the most important medical challenges of our time, both in the United States and throughout the world. We are indisputably in a new era where we have a large set of proven clinical tools that prevent and treat cardiometabolic disease, however our old models of clinical training and siloed care are barriers to implementation. By first establishing a vision of cardiometabolic medicine, and then a new Cardiometabolic Medicine specialty, we would be taking a small but critical step in the right direction towards providing the best possible comprehensive care for those with complex cardiometabolic disease.